Loading company
ONCBeone Medicines Ltd.$48BA+Built from 4D Molecular Therapeutics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes 4D Molecular Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$12.98+4.3%Nov 11 close
The latest quarter (ended September 30, 2026) is from 4D Molecular Therapeutics’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once 4D Molecular Therapeutics files it.
Grade C-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 22 quarters of 4D Molecular Therapeutics, Inc.’s grade history. The other 20 go back to August 2021.
